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We read with interest the comment by Sebastiani et al. on our
article on the ability of 13C2-aminopyrine breath test (13C-ABT)
to predict the progression of liver ﬁbrosis in patients with hepa-
titis C virus (HCV)-related chronic hepatitis C [1]. They remarked
on the existence of laboratory and instrumental tools [2] other
than 13C-ABT, largely validated and even suggested by current
guidelines [3], in the prediction of severity of HCV-related liver
diseases.
Liver ﬁbrosis, as evaluated on biopsy samples, is of crucial
importance for the diagnosis of severity of liver diseases and is
still the best prognosis predictor in patients with HCV-related
chronic hepatitis [4]. The quest for non-invasive procedures able
to accurately stage liver ﬁbrosis and to predict outcome has led to
various laboratory tests and imaging techniques. However, the
rate and speed of ﬁbrosis progression are highly variable, ranging
from slow to rapid progression, probably in relation to host char-
acteristics, external factors, co-infections and co-morbidities [4].
It is noteworthy that one of the major limitations of the invasive
and non-invasive methods currently available to stage liver ﬁbro-
sis is that none can predict the likelihood of disease progression
at an early stage of the disease.
Transient elastography and serum markers have a high accu-
racy in the diagnosis of liver ﬁbrosis for which they are recom-
mended by current guidelines [3]. However, they have been
proven to predict the outcome of HCV-related chronic disease
only in terms of liver-related complications and survival [5-7].
In contrast, thanks to the experimental design of our study, which
included only HCV-infected patients naïve to therapy, in absence
of liver cirrhosis and other causes of liver disease, who under-
went paired biopsies in a long-term follow-up (mean period
7 years), we were able to demonstrate that the 13C-ABT predicts
the likelihood of disease progression at an early stage of the dis-
ease. Thus, a comparison between the 13C-ABT and the other tests
mentioned by Sebastiani et al. in terms of diagnostic performance
and health costs is not feasible.
Given the rapidly changing therapeutic landscape of HCV-
related chronic diseases, it might become critical to identify
who should be treated now and who might best wait for treat-
ment. Thus, in the near future, the early identiﬁcation of the sub-
group of subjects at higher risk of liver ﬁbrosis progression could832 Journal of Hepatology 20be decisive in allocating healthcare resources and selecting anti-
viral treatment.
In conclusion, with the premise that further studies would be
advisable to further validate 13C-ABT, we believe that this test can
be a useful complementary tool to evaluate the outcome of
patients chronically infected with HCV.
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